Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0036341
Disease: Schizophrenia
Schizophrenia
0.340 AlteredExpression disease BEFREE MCHR1 expression is decreased in the prefrontal cortex of schizophrenia samples (FDR p< 0.05, CommonMind and PsychEncode combined datasets, N = 901) while PMCH is below the detection threshold. 31563948 2020
CUI: C0036341
Disease: Schizophrenia
Schizophrenia
0.340 Biomarker disease BEFREE Our results suggest that MCHR1 may influence schizophrenia susceptibility, in particular among men and patients responding to conventional (nonclozapine) treatment. 22081064 2012
CUI: C0036341
Disease: Schizophrenia
Schizophrenia
0.340 Biomarker disease PSYGENET Our results suggest that MCHR1 may influence schizophrenia susceptibility, in particular among men and patients responding to conventional (nonclozapine) treatment. 22081064 2012
CUI: C0036341
Disease: Schizophrenia
Schizophrenia
0.340 Biomarker disease PSYGENET Augmentation of disease risk was found for the complex genotype HM74[A,any]+MCHR1[T,any]+MCHR2[C,any] which conferred an OR maximal for the combined diagnostic category of schizophrenia plus bipolar disorder (1.70, p=0.003), carried by 30% of the cases. 19502010 2009
CUI: C0036341
Disease: Schizophrenia
Schizophrenia
0.340 Biomarker disease BEFREE Augmentation of disease risk was found for the complex genotype HM74[A,any]+MCHR1[T,any]+MCHR2[C,any] which conferred an OR maximal for the combined diagnostic category of schizophrenia plus bipolar disorder (1.70, p=0.003), carried by 30% of the cases. 19502010 2009
CUI: C0036341
Disease: Schizophrenia
Schizophrenia
0.340 GeneticVariation disease LHGDN To our knowledge this is the first study reporting association between GPR24 and BPD and SZ, suggesting that GPR24 variants may confer susceptibility to both disorders. 16741940 2006
CUI: C0036341
Disease: Schizophrenia
Schizophrenia
0.340 Biomarker disease PSYGENET To our knowledge this is the first study reporting association between GPR24 and BPD and SZ, suggesting that GPR24 variants may confer susceptibility to both disorders. 16741940 2006
CUI: C0036341
Disease: Schizophrenia
Schizophrenia
0.340 Biomarker disease BEFREE To our knowledge this is the first study reporting association between GPR24 and BPD and SZ, suggesting that GPR24 variants may confer susceptibility to both disorders. 16741940 2006
CUI: C0011570
Disease: Mental Depression
Mental Depression
0.330 Biomarker disease BEFREE Animal studies have shown that antagonists of receptor 1 of Melanin-Concentrating Hormone (MCH-R1) elicit antidepressive-like behavior, suggesting that MCH-R1 might be a novel target for the treatment of depression and supports the hypothesis that MCHergic signaling regulates depressive-like behaviors. 31376444 2019
CUI: C0011581
Disease: Depressive disorder
Depressive disorder
0.330 Biomarker disease BEFREE Animal studies have shown that antagonists of receptor 1 of Melanin-Concentrating Hormone (MCH-R1) elicit antidepressive-like behavior, suggesting that MCH-R1 might be a novel target for the treatment of depression and supports the hypothesis that MCHergic signaling regulates depressive-like behaviors. 31376444 2019
CUI: C0011570
Disease: Mental Depression
Mental Depression
0.330 Biomarker disease PSYGENET The data indicate that MCH1R participates in the modulation of depression-like behavior through a process that involves the CA1 region of the hippocampus, supporting the possible use of MCH1R antagonists in the treatment of depression. 22209364 2012
CUI: C0011581
Disease: Depressive disorder
Depressive disorder
0.330 Biomarker disease PSYGENET The data indicate that MCH1R participates in the modulation of depression-like behavior through a process that involves the CA1 region of the hippocampus, supporting the possible use of MCH1R antagonists in the treatment of depression. 22209364 2012
CUI: C0011570
Disease: Mental Depression
Mental Depression
0.330 Biomarker disease PSYGENET Preclinical evaluation of melanin-concentrating hormone receptor 1 antagonism for the treatment of obesity and depression. 19182070 2009
CUI: C0011581
Disease: Depressive disorder
Depressive disorder
0.330 Biomarker disease PSYGENET Preclinical evaluation of melanin-concentrating hormone receptor 1 antagonism for the treatment of obesity and depression. 19182070 2009
CUI: C0525045
Disease: Mood Disorders
Mood Disorders
0.330 Biomarker group PSYGENET We also comment on the utility of small-molecule MCHR1 antagonists for the treatment of obesity and affective disorders compared to existing therapies and provide a critical overview of the potential risks. 19418262 2009
CUI: C0525045
Disease: Mood Disorders
Mood Disorders
0.330 Biomarker group BEFREE We also comment on the utility of small-molecule MCHR1 antagonists for the treatment of obesity and affective disorders compared to existing therapies and provide a critical overview of the potential risks. 19418262 2009
CUI: C0011570
Disease: Mental Depression
Mental Depression
0.330 Biomarker disease PSYGENET Taken together, we suggest that antagonism of the MCHR1 receptor may provide a novel approach for the treatment of affective disorders, including depression, with a potentially increased efficacy in women. 16934771 2007
CUI: C0011570
Disease: Mental Depression
Mental Depression
0.330 Biomarker disease BEFREE Taken together, we suggest that antagonism of the MCHR1 receptor may provide a novel approach for the treatment of affective disorders, including depression, with a potentially increased efficacy in women. 16934771 2007
CUI: C0011570
Disease: Mental Depression
Mental Depression
0.330 Biomarker disease BEFREE MCHR1 antagonists might find an additional usage in the treatment of anxiety and depression disorders. 17655875 2007
CUI: C0011570
Disease: Mental Depression
Mental Depression
0.330 Biomarker disease PSYGENET MCHR1 antagonists might find an additional usage in the treatment of anxiety and depression disorders. 17655875 2007
CUI: C0011581
Disease: Depressive disorder
Depressive disorder
0.330 Biomarker disease BEFREE Taken together, we suggest that antagonism of the MCHR1 receptor may provide a novel approach for the treatment of affective disorders, including depression, with a potentially increased efficacy in women. 16934771 2007
CUI: C0011581
Disease: Depressive disorder
Depressive disorder
0.330 Biomarker disease BEFREE MCHR1 antagonists might find an additional usage in the treatment of anxiety and depression disorders. 17655875 2007
CUI: C0011581
Disease: Depressive disorder
Depressive disorder
0.330 Biomarker disease PSYGENET Taken together, we suggest that antagonism of the MCHR1 receptor may provide a novel approach for the treatment of affective disorders, including depression, with a potentially increased efficacy in women. 16934771 2007
CUI: C0011581
Disease: Depressive disorder
Depressive disorder
0.330 Biomarker disease PSYGENET MCHR1 antagonists might find an additional usage in the treatment of anxiety and depression disorders. 17655875 2007
CUI: C0525045
Disease: Mood Disorders
Mood Disorders
0.330 Biomarker group PSYGENET Taken together, we suggest that antagonism of the MCHR1 receptor may provide a novel approach for the treatment of affective disorders, including depression, with a potentially increased efficacy in women. 16934771 2007